Tramadol in first trimester pregnancy

The short version: the retrieved evidence does not contain a single study that directly measures the risk of birth defects or pregnancy loss after first-trimester tramadol exposure, so the question cannot be answered from these records.

The evidence here is about classification systems and general opioid use, not about tramadol’s specific fetal effects. One review notes that different pregnancy-safety rating systems assign tramadol conflicting labels—the EBM system rates it T/S (teratogenic/safe) during the peripartum period, but that rating is for late pregnancy, not the first trimester [1]. A large Quebec cohort found that 2.0% of pregnancies ending in delivery had a prescribed opioid in the first trimester, but it did not report outcomes by opioid type or by trimester of exposure [2]. Two case reports describe neonatal withdrawal after long-term maternal tramadol use, but neither addresses first-trimester exposure or malformations [3, 4].

What this means: there is no controlled human data in this retrieval comparing first-trimester tramadol-exposed pregnancies to unexposed pregnancies for rates of miscarriage, major birth defects, or other adverse outcomes. The absence of such studies in this search does not prove safety or harm—it proves the question was not answered by what was found.

My call: the evidence retrieved does not allow a conclusion about first-trimester tramadol safety. Confidence: not clear—the retrieval simply does not cover the question.